<DOC>
	<DOCNO>NCT01322893</DOCNO>
	<brief_summary>Women metastatic breast cancer , receive first line treatment kind ( chemotherapy , endocrine treatment treatment antibody ) include trial . In connection treatment , blood sample determination enumeration circulate tumour cell collect different time point . Serum plasma collect stored future analysis RNA DNA .</brief_summary>
	<brief_title>Enumeration Molecular Characterization Circulating Tumour Cells Women With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Women metastatic breast cancer ECOG performance status 02 Age over18 year Signed informed concent Predicted life expectancy 2 month Planned first line systemic treatment metastatic disease ( chemotherapy , antibody treatment endocrine treatment ) Standard image evaluation within 4 week inclusion Planned standard imaging within 16 week start therapy Prior medical therapy metastatic disease ( prior adjuvant chemotherapy , radiotherapy endocrine therapy permit ) Inability understand information study Other malignant disease exception curatively treat basal cell squamous cell cancer skin cancer situ cervix</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Circulating tumour cell</keyword>
	<keyword>CTC</keyword>
	<keyword>Prognostic factor</keyword>
	<keyword>Treatment response</keyword>
</DOC>